Appropriate Evaluation of Antiviral Therapy With Nirmatrelvir-ritonavir in Hospitalized Patients
NCT ID: NCT05749445
Last Updated: 2023-03-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
200 participants
OBSERVATIONAL
2022-12-15
2023-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Efficacy and Safety of Azvudine vs. Nirmatrelvir-Ritonavir in the Treatment of COVID-19 Infection
NCT05697055
A Study to Learn About the Study Medicines (Nirmatrelvir Plus Ritonavir) in People Aged 12 Years or Older With COVID-19 and a Compromised Immune System
NCT05438602
A Real-world Retrospective Study of Disease Outcomes in Non-severe COVID-19 Patient
NCT05489874
Real World COVID-19 Antiviral Effectiveness Research
NCT05638919
A Clinical Study to Evaluate the Efficacy and Safety of SIM0417 Orally Co-Administered With Ritonavir in Symptomatic Adult Participants With Mild to Moderate COVID-19
NCT05506176
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Nirmatrelvir-Ritonavir
Hospitalized patients receiving at least one dose Nirmatrelvir-Ritonavir
Nirmatrelvir-Ritonavir
Nirmatrelvir-Ritonavir
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nirmatrelvir-Ritonavir
Nirmatrelvir-Ritonavir
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hangzhou Cancer Hospital
OTHER
First People's Hospital of Lin'an District
UNKNOWN
First People's Hospital of Yuhang District
UNKNOWN
First People's Hospital of Hangzhou
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Changcheng Shi
Role: PRINCIPAL_INVESTIGATOR
First People's Hospital of Hangzhou
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Changcheng Shi
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Lamb YN. Nirmatrelvir Plus Ritonavir: First Approval. Drugs. 2022 Apr;82(5):585-591. doi: 10.1007/s40265-022-01692-5.
Akinosoglou K, Schinas G, Gogos C. Oral Antiviral Treatment for COVID-19: A Comprehensive Review on Nirmatrelvir/Ritonavir. Viruses. 2022 Nov 17;14(11):2540. doi: 10.3390/v14112540.
Related Links
Access external resources that provide additional context or updates about the study.
COVID-19 Drug Interactions
Fact sheet for healthcare providers: Emergency use authorization for Paxlovid
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AEATN
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.